Agilvax Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Series A1
  • Latest Deal Amount
  • $4.5M
Latest Deal Amount
  • Investors
  • 11

Agilvax General Information

Description

Developer of targeted antibody-based cancer immunotherapies and vaccines intended to fight cancer. The company's lead product is an antibody-drug conjugate that specifically binds SLC7A11 (xCT), a protein that is overexpressed on many different tumor types, including colorectal cancer, lung cancer, breast cancer, and liver cancer.

Contact Information

Website
www.agilvax.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 5901 Indian School Road North East
  • Albuquerque, NM 87110
  • United States
+1 (505) 000-0000

Agilvax Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Agilvax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series A1) 27-Aug-2019 $4.5M 000.00 Completed Pre-Clinical Trials
9. Accelerator/Incubator 16-Apr-2018 00.00 Completed Pre-Clinical Trials
8. Grant 01-Jan-2018 00.00 00.00 Completed Pre-Clinical Trials
7. Accelerator/Incubator 31-Mar-2017 00.00 Completed Pre-Clinical Trials
6. Later Stage VC (Series A) 24-Feb-2017 00.000 00.00 00.00 Completed Pre-Clinical Trials
5. Grant 06-Jul-2016 00000 00.000 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 31-Jul-2014 000 00.000 00.000 Completed Pre-Clinical Trials
3. Seed Round 12-Nov-2013 00.00 00.000 000 Completed Pre-Clinical Trials
2. Accelerator/Incubator $158K Completed Pre-Clinical Trials
1. Seed Round 24-Aug-2011 $158K $158K Completed Pre-Clinical Trials
To view Agilvax’s complete valuation and funding history, request access »

Agilvax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Seed 1,772,740 $0.001000 $1 $1 1x $1 13.43%
To view Agilvax’s complete cap table history, request access »

Agilvax Executive Team (11)

Name Title Board Seat Contact Info
Les Stewart Chief Operating Officer
Joseph Patti Ph.D Chief Executive Officer, President & Board Member
You’re viewing 2 of 11 executive team members. Get the full list »

Agilvax Board Members (9)

Name Representing Role Since
Brad Vale Ph.D Self Board Member 000 0000
Brian Birk Sun Mountain Capital Board Member 000 0000
Ebetuel Pallares Ph.D Joseph Advisory Services Chairman 000 0000
Faith Charles JD Self Board Member 000 0000
Joseph Patti Ph.D Self Chief Executive Officer, President & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Agilvax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agilvax Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Springboard Enterprises Accelerator/Incubator Minority 000 0000 000000 0
New Mexico State Investment Council Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »